Scandinavia’s Fastest-Growing CRO Appoints Three Life Science Experts
News May 13, 2016
PCG Clinical Services AB has announced the appointment of three industry specialists to its Business Development team, supporting the rapidly growing company’s extension into international biotech and pharmaceutical markets. The three new recruits – Roger Price, Antonio Mastroianniand Heidi Pavliska – bring decades of experience in clinical development across the US, Europe and Scandinavia, and a mixture of perspectives through working in large pharma, biotech, CRO and non-profit organisations.
“We’re delighted to welcome Roger, Antonio and Heidi to the company. Their impressive scientific and international business expertise will complement our existing team’s strengths in understanding the pressing needs of the clinical trials industry,” said Andy Babington, CEO, PCG Clinical Services. “This is an exciting period of growth for PCG and these new hires demonstrate our commitment to delivering excellence for our partners as well as achieving our goals.”
Roger Price joined as Senior Business Development Manager for PCG Clinical Services in April 2016. He has nearly 40 years’ experience in the pharma, CRO, data management and clinical supplies industries. He previously held positions at companies including Cambridge Cognition, Paragon and Worldwide Clinical Trials, and has gained invaluable cross-industry perspectives on clinical trials management.
Antonio Mastroianni, Business Development Manager, brings experiences from a diverse background in corporate, non-profit, governmental and international standard-setting bodies to PCG Clinical Services. He joined the company in April 2016 from his own systems-based thinking consultancy, Aros Performance Management, where he worked with organisations focused on social innovation, including improving clinical trials. Antonio previously held positions as the Head of Pharmacovigilance Services and, more recently, Chief Operating Officer at the WHO Collaborating Centre for International Drug Monitoring (Uppsala Monitoring Centre).
Heidi Pavliska began her business career with the start-up of a biotech company in Amsterdam, the Netherlands, and has had 17 years’ experience working with life science, drug development companies and CROs in the US and Scandinavia, including AMRI, Evotec, Aptuit and, most recently, Accutest Research Laboratories. She joined PCG Clinical Services as Business Development Managerin May 2016.
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE